Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Type: Oral Abstract Session

Time: Tuesday June 6, 9:45 AM to 12:45 PM

Location: E450ab

Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).

Sub-category:
Myeloproliferative Syndromes (MPD)

Category:
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Meeting:
2017 ASCO Annual Meeting

Abstract No:
7000

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 7000)

Author(s): Ruben A. Mesa, Jean-Jacques Kiladjian, John V. Catalano, Timothy Devos, Miklos Egyed, Andrzei Hellman, Donal McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason R. Gotlib; Mayo Clinic Cancer Center, Scottsdale, AZ; Saint-Louis Hospital (AP-HP) and Paris Diderot University, Paris, France; Monash University, Melbourne, Australia; University Hospitals Leuven, Leuven, Belgium; Kaposi Mor Teaching Hospital, Kaposvar, Hungary; Medical University of Gdańsk, Gdańsk, Poland; King’s College Hospital NHS Foundation Trust, London, United Kingdom; University of Miyazaki, Miyazaki, Japan; Emory University School of Medicine, Atlanta, GA; Gilead Sciences, Inc., Foster City, CA; Hospital Clínic de Barcelona, Barcelona, Spain; Stanford University Medical Center, Stanford, CA

Abstract Disclosures

Abstract:

Background: MMB, an oral JAKi, has been shown in early trials to reduce spleen volume, improve disease associated symptoms (Sx) and improve RBC transfusion (Tx) requirements in patients (pts) with MF. This study was designed to test non-inferiority of MMB vs RUX in splenic volume reduction and Sx amelioration, and superiority in Tx requirement, in JAKi naïve MF pts. Methods: Eligibility: MF, IPSS high risk, Int-2, or symptomatic Int-1; palpable spleen ≥5cm; platelets ≥ 50 K/μl, and no Gr ≥2 peripheral neuropathy (PN). Stratification by Tx dependency and platelets (<100, 100-200 and >200 K/μl). Pts were randomized 1:1 to 24 wks of MMB 200 mg qd + RUX placebo or RUX 20 mg bid (or modified per label) + MMB placebo, after which all pts could receive open label MMB. Assessments: spleen volume by MRI, and pt reported Sx using a daily eDiary of modified MPN-SAF Total Sx Score (TSS). Primary endpoint was splenic response rate (SRR; ≥35% reduction in volume from baseline) at 24 wks. Secondary endpoints, evaluated sequentially at 24 wks, were rates of TSS response (≥50% reduction from baseline), RBC Tx independence (TI), RBC Tx dependence (TD) and of RBC Tx.Results: 175 of 215 (81%) and 201 of 217 (93%) pts randomized to MMB and RUX, respectively, completed the 24 wk DB phase. Efficacy results are shown in Table. Most common Gr ≥3 AEs in the DB phase with MMB were thrombocytopenia (7%) and anemia (6%), and with RUX were anemia (23%), thrombocytopenia (5%) and neutropenia (5%). Gr ≥3 infections occurred in 7% of MMB and 3% of RUX pts. Treatment emergent PN occurred in 22 (10%) of MMB (all Gr ≤2) and 10 (5%) of RUX (9 Gr ≤2, 1 Gr 3) pts in DB phase, none discontinuing study drug for PN. Overall, AEs led to study drug D/C in 13% of MMB and 6% of RUX pts in DB phase. Conclusions: In pts with JAKi naive MF, 24 weeks of MMB is non-inferior to RUX for spleen response but not for symptom response. MMB treatment is associated with a reduced transfusion requirement. NCT01969838.

EndpointsMMBRUXP-Value
Spleen response rate, %26.529.00.011a
TSS response rate, %28.442.20.98 a
TI rate, %66.549.3< 0.001b
TD rate,%30.240.10.019b
Tx rate (units/month), median0.00.4< 0.001b

aTest for non-inferiority; bTest for superiority, all values nominally significant.

 
Other Abstracts in this Sub-Category:

 

1. Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).

Meeting: 2017 ASCO Annual Meeting Abstract No: 7001 First Author: Claire N. Harrison
Category: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Myeloproliferative Syndromes (MPD)

 

2. Phase I/II trial of glasdegib in patients with primary or secondary myelofibrosis.

Meeting: 2017 ASCO Annual Meeting Abstract No: 7061 First Author: Aaron Thomas Gerds
Category: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Myeloproliferative Syndromes (MPD)

 

3. Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients.

Meeting: 2017 ASCO Annual Meeting Abstract No: 7062 First Author: Swapna Narayana
Category: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Myeloproliferative Syndromes (MPD)

 

More...